Actually, $400K for a treatment course at 10mg/kg, assuming proportional pricing. The market likes it, evidently. Other than a few prints in Sep 2010 (following positive Apixaban news), BMY traded higher today than at any time since 2007.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”